Find an expert

Associate Professor Jakob Begun is the IBD Group leader in the Immunity, Infection, and Inflammation Program at Mater Research University of Queensalnd, and has a basic and translational laboratory at the Translational Research Institute in Brisbane. He is an Associate Professor in the University of Queensland Faculty of Medicine. After completing his Bachelor of Science at Cornell University Jakob attended Cambridge University where he completed an MPhil in Biochemistry. He then moved on to Harvard Medical School where he completed his MD and PhD in genetics studying the host pathogen interaction using C. elegans as a model system. He completed his clinical training in internal medicine at Brigham and Women’s hospital and went on to complete general gastroenterology training at Massachusetts General Hospital (MGH) as well as advanced training in the treatment of Inflammatory Bowel Disease (IBD).

Dr Begun first joined Mater Research - University of Queensland in 2014, and at the same time received a clinical staff appointment in Gastroenterology at the Mater Hospital Brisbane. His clinical activities are focussed on the treatment and mangement of patients with IBD. He is the director of the IBD unit at the Mater Hospital Brisbane and at the Mater Young Adult Health Centre Brisbane .In January 2015 he was awarded the University of Queensland Reginald Ferguson Fellowship in Gastroenterology to support his research activity. He leads a basic and translational laboratory at the Translational Research Institute investigating the interaction between the innate immune system and the gut microbiome, as well as genetic contributions to disease. He also performs clinical research examining predictors of response to therapy, minimising barriers of care for adolescents and young adults with IBD, improving outcomes in pregnancy and IBD, and the use of intestinal ultrasound in IBD. He is the chair of the Gastroenterology Society of Australia-IBD Faculty and of the president of the Gastroenterology Network of Intestinal Ultrasound (GENIUS).

Gabrielle Belz originally trained in veterinary medicine and surgery and received her PhD in understanding the organisation of lymphatics and lymphoid tissues at The University of Queensland. After a short stint in Canada to work on B cells, she moved to St Jude Children’s Research Hospital to work with Peter Doherty supported by an NHMRC CJ Martin Fellowship. Here she established a number of systems that now allow tracking of virus-specific T cells and established the paradigm changing notion that CD4 T cell help was required for generating antiviral responses. She returned to The Walter and Eliza Hall Institute of Medical Research and uncovered the identity of the key dendritic cells necessary for initiating antiviral infections. Subsequently she was awarded the Burnet Prize and NHMRC Elizabeth Blackburn Fellowship. Her research contributions have been recognized by a number of awards including a Wellcome Trust Overseas Fellowship, HHMI international fellowship, ARC Future fellowship, Doctor of Veterinary Science and the Gottschalk Medal (Australian Academy of Science). Her laboratory focuses on deciphering the key cellular and transcriptional signals of protective immunity particularly by T cells and in understanding how innate immune cells develop and make novel contributions to mucosal immune defence.

Professor Antje Blumenthal combines her expertise in immunology and microbiology to lead research on molecular mechanisms that control immune responses to infection, alongside more recently developed research on new antimicrobials. The overall goal of her research is to improve our ability to treat severe bacterial infections as part of the global efforts to overcome the threat posed by antibiotic-resistant bacteria. Prof Blumenthal graduated with a major in Microbiology from the Christian-Albrechts-University in Kiel, Germany, pursued PhD research in Immunology at the Leibniz Research Center for Medicine and Biosciences Borstel, Germany, and undertook postdoctoral training at Weill Cornell Medical College, New York, USA. She joined The University of Queensland Diamantina Institute in 2010 where she leads the Infection & Inflammation Group, fostering cross-disciplinary collaborations with immunologists, microbiologists, chemists, clinical research teams and industry partners. Her research is enabled by major funding from international and national agencies, and has been recognised internationally and nationally by prestigious awards, speaking invitations at eminent conferences and institutions, invitations to peer-review for esteemed journals and funding agencies. Prof Blumenthal is an enthusiastic undergraduate teacher and research student advisor. She is proactive in advancing the careers of junior scientists, leads the development and implementation of initiatives that promote equity, diversity and inclusion in science, and a positive workplace culture. Through leadership roles within the University and professional societies as well as editorial roles for international journals, Prof Blumenthal actively contributes to the scientific community.

Dr. Sabrina Sofia Burgener is Deputy Lab Head of the Disease Modelling Team of the Inflammasome Laboratory and Senior Research Fellow in Immunology at the Institute for Molecular Bioscience at The University of Queensland.

As Deputy Lab Head of the Inflammasome Group at the Institute for Molecular Bioscience (IMB), Dr. Burgener is an innate immunologist with over 12 years of cross-functional expertise in immunology, disease modelling and molecular biology. My research program focuses on a holistic understanding of inflammasome signalling in pre-clinical disease models to harness the development of new diagnostics and anti-inflammatory therapeutics.

After obtaining her professional training as a Veterinary Technician, they completed their PhD in Immunology under supervision of A/Prof. Benarafa at the University of Bern, Switzerland in 2017.

For their work on the cytoprotective role of Serpinb1 and Serpinb6 in neutrophils, they received several international awards such as the Society of Leukocyte Biology Presidential Award in 2016 and the Dr. Lutz Zwillenberg Prize in 2020. Before joining the Inflammasome Lab in 2019, Dr. Burgener had been a Postdoctoral Researcher at the Institute of Virology and Immunology at the Vetsuisse Faculty of the University of Bern. In the Schroder lab, Dr. Burgener leads a team of Honour and PhD students, interested in understanding how caspase-1 drives inflammatory diseases and if targeting caspase-1 in diseases such as non-alcoholic steatohepatitis and Alzheimer’s disease comes at the cost of increased susceptibility to infection. Their research is funded by SNSF Postdoc Mobility Fellowship (2020-2022) and the Novartis Foundation for Medical-Biological Research Fellowship (2022-2023).

Dr Jenny Fung is a senior postdoctoral research fellow and lecturer of pharmacology course at the School of Biomedical Sciences (SBMS), UQ. She is an emerging researcher in the reproductive disease field with experience in molecular biology techniques, genetics, functional genomics, statistical and high-throughput computational skills, ex-vivo and in-vivo models of diseases, as well as industry engagement. In 2013, she was awarded a PhD at UQ and continued post-doctoral research in Professor Grant Montgomery's laboratory at QIMRB and IMB, in the field of genetics and genomics with a focus on functional genomics studies in complex diseases and a special interest in endometriosis. Her research has led to the seminal publication identifying the genetics of gene expression in endometrium and the role of gene regulation underlying endometriosis-related pathogenesis. In 2019, she joined Professor Trent Woodruff’s laboratory at SBMS, UQ to work on immunotherapy development for cancer through funding from Pfizer, where she performed immune cell functional assays and genomics analyses. Dr Fung is in a unique position to perform both the wet and dry lab components of multi-disciplinary research. She is currently co-leading multiple projects, where she is contributing her expertise on genetics and functional genomics on immunology to discover target genes and putative pathways underlying disease progression, with an ultimate goal to develop potential effective drugs for reproductive and brain disorders.

Dr Kate Gartlan is an immunologist with considerable expertise in cellular immunology, particularly using in vivo models of inflammation to investigate immune-modulation and T cell polarisation. Dr Gartlan began her research career at WEHI within Professor Ken Shortman’s laboratory developing strong skills in both molecular and cell biology, where she became interested in the early factors that influence adaptive immunity. She completed her PhD in 2009 at the Burnet Institute working with Associate Professor Mark Wright, where she studied functional redundancy between Tetraspanin proteins in the immune system. To advance her understanding of inflammatory mediators and adaptive immune polarisation, she moved to the University of Oxford and took up a postdoctoral position within the Sir William Dunn School of Pathology. Working with Professor Quentin Sattentau, she investigated novel ways to modulate T cell polarisation and influence B cell responses to HIV vaccines.

After returning to Australia, she has worked with Professor Geoff Hill at QIMR Berghofer investigating novel therapies to treat graft-versus-host disease (GVHD) in allograft recipients. Dr Gartlan has held active teaching roles within both university and research institute environments, contributing to undergraduate science and medicine programs at both departmental and college levels.

Her main research interests at present surround the role of IL-17 & IL-22 in GVHD, potential therapeutics to modulate T cell polarisation after allogeneic bone marrow/stem cell transplant (BMT/SCT), as well as developing novel inhibitors of graft rejection to improve engraftment after BMT/SCT.

Dr. Richard Gordon leads a multi-disciplinary, industry-partnered research program in Translational Neuroscience which integrates immunology, drug development, pharmacology, metabolomics and microbial metagenomics. His group aims to understand and therapeutically target key pathological mechanisms which drive the onset and progression of neurodegenerative disorders such as Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Their work combines target validation studies in human patients with mechanistic insights from disease models to develop and test novel therapeutic strategies that can be translated towards clinical trials.

Key research themes within this program include:

• Understanding how chronic immune and inflammasome activation contribute to neurodegeneration in the CNS
• The role of gut dysbiosis and gastrointestinal dysfunction in Parkinson’s disease pathophysiology
• Therapeutic targeting of the gut-brain axis for neuroprotection
• Drug discovery, development and repositioning for novel therapeutic targets
• Discovery and validation of clinical biomarkers for PD and ALS
• Clinical trials for disease-modifying therapeutic strategies

I am a Research Fellow and Leader in Pain Relief Innovation at AIBN, UQ. My research interests sit at the interface of drug delivery and the pain field. My overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management. I am looking for highly motivated postgraduate students.

I also enjoy volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). I am currently serving as guest editor of Pain Research and Management.and JoVE Methods Collection.

Research Interests

My research is focusing on nano-based drug formulation and development to improve chronic pain management. I have a broad and unique background in both pharmacology and drug delivery systems, with specific expertise in the development of novel drug products and testing their analgesic efficacy and safety including pharmacokinetic and pharmacodynamic studies. To date, I have established five different techniques to produce painkiller–loaded nanoparticles and nanofibers aimed at improving pain relief for patients where currently available pain-killers either lack efficacy or produce dose-limiting side-effects. For example, there is a small and very potent peptide that has been on the market as a chemical for over 10 years but which cannot be used as a therapeutic due to its short half-life and poor oral bioavailability. In the form of my nanoparticles, that peptide has the potential to become an oral treatment for improving pain management in patients whose pain is currently poorly alleviated by clinically used pain-killers. I have significant expertise in the use of rodent pain models to assess novel analgesics, and I have received excellent training in conducting research in accordance with the stringent requirements of the Quality Management System (quality accreditations (GLP and ISO17025) from NATA). Together, my knowledge, skills and experience will facilitate the efficient translation of my research from the bench to the clinic.

The current focus of the lab is on the development of drug-products to solve one of the largest unmet medical needs in the pain field through use of sustainable materials. 1) We are developing multifunctional sutures including biodegradable pain relief sutures. 2) We are developing my innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. We are establishing a platform for the development of safe, effective delivery for other small molecule peptide drugs in general to pave their way to clinical trials. 3) Our research also investigates the role of C5a and C3a, estrogen, etc. in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain and OA pain.

We work in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. We also provide preclinical evaluation of novel compounds and formulations.

Dr. Larisa Labzin studies how our innate immune system detects viral infections and how it decodes different signals to mount an appropriate immune response. Dr. Labzin's interest in innate immunity started during her honours training with Prof. Matt Sweet at the IMB, looking at how inflammatory signalling is regulated in macrophages. After gaining more experience while working as a research assistant for Prof. Sweet, she moved to Germany to the University of Bonn for her PhD. At the Univeristy of Bonn, Dr. Labzin investigated the anti-inflammatory effects of High-Density Lipoprotein with Prof. Eicke Latz. Here she discovered novel regulatory pathways that control inflammation. Dr. Labzin then moved to Cambridge, UK as an EMBO postdoctoral fellow to work with Dr. Leo James at the Medical Research Council Laboratory for Molecular Biology. In Dr. James' lab Dr. Labzin focused on how viruses are sensed by the innate immune system to trigger inflammation. In particular, Dr Labzin investigated how antibodies change the way viruses trigger inflammation. While in Cambridge, Dr. Labzin was awarded an NHMRC CJ Martin Fellowship to return to Australia. Larisa returned to the IMB in September 2019 to work with Prof. Kate Schroder. Dr. Labzin is an IMB Fellow and leads an independent research team studying inflammation in response to influenza and SARS-CoV-2.

Dr Lee is a mid-career researcher with training in neuroscience, and additional experience in pharmacology and immunity. He completed his Ph.D. at the University of Queensland (UQ) in 2014 and continued his post-doctoral research studies in neuroinflammation and neurodegenerative diseases. He is currently a Senior Research Fellow and Group Leader at UQ's School of Biomedical Sciences, where he focusses on innate immune and inflammatory pathways including the complement system and inflammasomes in motor neuron disease (amyotrophic lateral sclerosis), Huntington’s disease, and Parkinson’s disease. Dr Lee’s research has demonstrated the therapeutic potential of multiple anti-inflammatory drugs targeting innate immune-mediated neuroinflammation to reduce neuronal cell death in animal models of neurodegenerative disease. He is also interested in the links between the immune system, stress response, and energy metabolism in neurodegeneration.

A/Prof Barbara Rolfe is a Group Leader at the Australian Institute for Bioengineering and Nanotechnology. A/Prof Rolfe is an immunologist and cell biologist, whose major research interests are the role of the innate immune system in cancer, the identification of novel therapeutic strategies for cancer, and nanomaterial safety. Her research has led to the identification of a previously unknown mechanism by which dysregulation of the immune system contributes to cancer development and growth, and provided information regarding the immune response to nanomaterials and the influence of physicochemical characteristics on biodistribution and cellular uptake. A/Prof Rolfe has used mouse models and small peptide agonists and antagonists to investigate the role of the innate immune system in tumour development and growth. This research demonstrated for the first time an important role for complement proteins in promoting tumour growth via regulation of immunosuppressive innate immune cells. Ongoing research is aimed focussed on gaining a better understanding of the role of complement proteins in tumour growth, developing novel immunotherapeutic strategies for cancer and investigating the application of nanomaterials for targeted delivery of anti-cancer drugs.

Prof Katharina Ronacher obtained an MSc degree in Medical Biochemistry from the University of Vienna (Austria). Thereafter, she was awarded a prestigious fellowship from the Austrian Ministry of Science and Technology to complete a PhD at the University of Cape Town (South Africa). She completed her post-doctoral fellowship at Stellenbosch University, where she was subsequently offered a faculty position. Prof Ronacher was Senior Scientist on several large clinical research trials funded by the Bill and Melinda Gates Foundation, the European Union and the US National Institutes of Health with focus on identification of biomarkers for tuberculosis (TB) treatment response. In parallel, she established her independent research group investigating how endocrine factors impact immune responses to TB, for which she received uninterrupted funding from national and international funding bodies since 2008. In 2015, she was awarded a NIH R01 grant for her ground-breaking research into the underlying immunological and metabolic mechanisms of increased susceptibility of diabetes patients to TB. With this grant she has lead the international ALERT Consortium with clinical field sites in South Africa and at the Texas/Mexico border.

She relocated to Brisbane in 2017, where she now heads the Infection, Immunity and Metabolism group at the Mater Research Institute – University of Queensland, but continues to collaborate with clinicians and researchers in South Africa, the USA and Europe and holds an affiliate appointment as Professor Extraordinary at Stellenbosch University.

Prof Ronacher's current research investigates the underlying immunological mechanisms contributing to more severe bacterial and viral respiratory infections in obesity and diabetes. Her research provides critical insights into the role of cholesterol and its derivatives in regulation of inflammation in the lung and how this knowledge can be exploided for novel therapeutic approaches to treat respiratory infections.

Dr Tom Schultz is a molecular immunologist and early career researcher at the UQ Frazer Institute who studies the molecular and cellular biology of innate immune receptors. His research primarily focuses on molecular mechanisms of Toll-like receptor (TLR) signalling in the context of mycobacterial and Gram-negative bacterial infection of macrophages.

Dr Sehgal completed his at the Roslin Institute, University of Edinburgh (UK) (2013-2017), where he developed a long-term research passion for investigating gut homeostasis and what happens during dysfunction and disease. In 2018, Dr Sehgal joined the Mater Research Insitute as a Research Officer to research the role of macrophages in growth and development. In October 2022, Dr Sehgal joined Wesley Research Institute as Senior Research Officer within the Coeliac Disease and Immune Health Program where he is leading translatable Coeliac Disease research.

Critical Care Medicine focuses on supporting patients, often with one or multiple organ failures. Based at the largest Australian cardiac hospital, our research investigates better ways to support patients with heart and/or lung failure. We explore technological, pharmacological and engineering advances that could help our patients to live longer and better. Our group is world-renowned for clinically relevant large animal models, including heart failure, respiratory failure (ARDS), heart transplantation, sepsis, cardiogenic shock, and more. All our studies use hospital-grade equipment and follow the same clinical guideline to maximise translation. We actively take on honours, MPhil and PhD students from multi-disciplinary backgrounds (science, engineering, medicine, allied health), with a successful track record in supporting our students to secure their own grants and funding. Students are expected to contribute to other studies of the group. For more information about the group, please visit ccrg.org.au, and email if you are interested to join us.

The Vukovic laboratory investigates how brain function is sculpted and influenced by the immune system. Specifically, we examine the role of brain’s main resident immune cell population (i.e. microglia), as well as various peripheral immune cells, on learning and memory in mice. We are interested in defining the contribution of immune cells to such higher cognitive tasks, including for neuroinflammatory conditions where learning and memory deficits can occur, e.g. following traumatic brain injury, cancer treatment, and ageing. We have established an array of genetic and pharmacological tools alongside robust behavioural assays to directly probe the function of these immune cells in both the healthy and diseased brain. The ultimate goal of our work is to link cellular and molecular events to altered behaviour, and to harness the brain’s intrinsic regenerative potential for stimulating optimal cognitive function.

A neuroimmunologist, Dr Vukovic received her PhD in 2008 from The University of Western Australia after working on the repair of injured nerve cell connections. She joined QBI in 2009 to work in Professor Perry Bartlett’s laboratory as a Postdoctoral Research Fellow, before being awarded a Queensland Government Smart Futures Fellowship to continue her research into the importance of adult neurogenesis for behaviour and how microglia influence this process in ageing. Dr Vukovic demonstrated that microglia can exert a dual and opposing influence over adult neurogenesis (the birth of new neurons) in the hippocampus under different physiological conditions, namely exercise and ageing, and that signalling through the chemokine receptor, CX3CR1, critically contributes towards this (Vukovic et al., 2012, J Neurosci). Dr Vukovic also generated novel evidence that ongoing neurogenesis in the adult hippocampus is critical for new learning but does not play a role in memory recall (Vukovic et al., 2013, J Neurosci).

Dr Vukovic was awarded an ARC Discovery Early Career Researcher Award (2015-2018) and was jointly appointed as a group leader by the UQ School of Biomedical Sciences (SBMS) and QBI in 2015. She heads the Neuroimmunology and Cognition team investigating the interactions between the brain and the immune system in health and disease.

Currently, the group is working on three main projects:

1. Identification of microglia-derived molecules that support neuronal survival and stimulate neural stem/progenitor cell expansion
2. Characterisation of immune cell contribution to changes in neuronal connectivity
3. Immune cell responses to cancer treatment, and their effect on learning and memory

Dr Ran Wang graduated with her PhD in 2015, and after undertaking a postdoc position in Scripps Research, USA returned to Australia in 2017. She is now a Senior Postdoctoral Researcher supported by the prestigious Bushell Postdoctoral Research Fellowship from the Gastroenterology Society of Australia. Dr Wang is interested to understand the nature of inflammation in gut and lung and investigate the local and systemic impacts of chronic gut inflammation. In addition to a growing track-record in the mucosal immunology field, she is also building an inter-disciplinary research profile in material science and nanotechnology for drug delivery and immune modulation. She is the Associate Editor of Frontier of Cellular and Infection Microbiology Journal since 2018.